AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04085354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine and folic acid.
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
Study NCT04085354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine and vitamin B12
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
Study NCT02635503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transrectal specimen extraction
Description: After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
Study NCT02635503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic surgery
Description: High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
Study NCT02551874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin, Onglyza
Description: Tablets, Oral, 5mg , Once daily, 24 weeks
Study NCT02551874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin, Farxiga
Description: Tablets, Oral, 10mg , Once daily, 24 weeks
Study NCT02551874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine insulin
Description: 100 Units/ml solution for injection in a prefilled SoloStar pen
Study NCT02551874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
Study NCT02203305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
Study NCT02203305 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
Study NCT03015662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling Therapy
Description: Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
Study NCT03015662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Therapy
Description: Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
Study NCT02679924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid filler
Description: The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
Study NCT02679924 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
Study NCT01065662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given on days 1, 8, 15 and 22 of each cycle
Study NCT01065662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib
Description: Taken orally daily
Study NCT04386798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: survey work
Description: Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
Study NCT00659867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes
Description: Standard endoscopy with random and targeted biopsies
Study NCT01493440 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: atosiban
Description: Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Study NCT01491802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA/LABA
Description: GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
Study NCT01491802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
Study NCT01140477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Accommodating Lens
Description: Toric accommodating lens implanted after cataract extraction
Study NCT04466657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidation Therapy
Description: Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
Study NCT04466657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
Study NCT04466657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
Study NCT03713112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weekly MDT deprescribing rounds for certain drugs
Description: * Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care
Study NCT01342809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow up
Description: Follow up, consultations with general practitioner, written guidelines, supervision.
Study NCT03851536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound Guided ET
Description: Use of TVUS to guide ET
Study NCT03851536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transabdominal Ultrasound Guided ET
Description: Use of TAUS to guide ET
Study NCT01409382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily brisk walking plus a carbohydrate-restricted diet
Description: Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
Study NCT04166188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar erector spinae plane block
Description: Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
Study NCT02311075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
Study NCT03247023 — intervention group
Intervention type: DEVICE
Intervention: Implantation of Integra Cadence Total Ankle Sysyem
Description: Primary Ankle Arthroplasty
Study NCT01079260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard ONS
Description: Standard ONS
Study NCT01079260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Energy, low volume ONS
Description: High energy, low volume ONS
Study NCT01250717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Description: Taken orally three times a day for 5 days for the first part of every three week cycle
Study NCT01250717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Given subcutaneously for 4 doses every three months
Study NCT01250717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Taken orally once a day for 6 months
Study NCT01250717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: after the chemo and hormonal therapy all patients have a radiacal prostatectomy
Study NCT01789333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Light with irradiance exposure of 9 mW/cm2
Description: The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes).
Study NCT01789333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 0.1% ophthalmic solution
Description: The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin).
Study NCT00635362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Description: Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
Study NCT00635362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Description: Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
Study NCT02144311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Study NCT02144311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT01559649 — intervention group
Intervention type: BEHAVIORAL
Intervention: Establishing Validity and Reliability
Description: Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
Study NCT05397002 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation
Description: preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
Study NCT00603824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux
Description: fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg
Study NCT00603824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: argatroban or lepirudin
Description: continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
Study NCT00796367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 7.5 mg phentermine and 46 mg topiramate
Study NCT00796367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00796367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 15 mg phentermine and 92 mg topiramate
Study NCT04155567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-123
Description: TAK-123 infusion
Study NCT01718860 — intervention group
Intervention type: PROCEDURE
Intervention: Quantitative measurement of neuromuscular transmission
Description: Quantitative measurement of neuromuscular transmission with train-of-four watches.
Study NCT01140477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accommodating Lens
Description: Accommodating lens implanted after cataract extraction
Study NCT04400279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga group
Description: At-home yoga exercise instruction provided by a mobile/tablet app or through a computer web browser
Study NCT04400279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training group
Description: At-home HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
Study NCT04400279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination
Description: At-home yoga \& HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
Study NCT00779142 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate intravenous 25mg/ml
Description: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
Study NCT03808415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-driven
Description: The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
Study NCT02400723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
Study NCT02400723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
Study NCT04016454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: There will be one complete handover
Study NCT00664079 — intervention group
Intervention type: OTHER
Intervention: Blood draws
Description: 17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
Study NCT02400723 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation (Placebo)
Description: DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
Study NCT03034954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active HD-tDCS
Description: Participants will receive active HD-tDCS at 3mA for 20 minutes
Study NCT03034954 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS
Description: Participants will receive sham HD-tDCS
Study NCT03729336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midstream urine collection device
Description: Non-invasive midstream urine collection device
Study NCT02690831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle training (IMT)
Description: Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
Study NCT02690831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT + Manual Therapy and Motor Control Exercise
Description: IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
Study NCT02690831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerbreathe
Study NCT02690831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powerbreathe
Study NCT02570802 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasonographic examination
Study NCT02294214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatial Repellent product with active ingredient
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
Study NCT02294214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active ingredient
Description: Transfluthrin (Active ingredient)
Study NCT02294214 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spatial Repellent product without active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
Study NCT03487289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural orifice
Description: laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
Study NCT00310817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, unadjuvanted
Study NCT02657304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching group
Description: patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.